If you are looking for big returns in 2026, then read on!
That's because experts believe that the ASX shares in this article have the potential to smash the market next year.
Here's what they are recommending to clients for the year ahead:
Image source: Getty Images
Catapult Sports Ltd (ASX: CAT)
The team at Morgans thinks that this sports technology company's shares could be strong performers in 2026.
Its analysts have put a buy rating and $6.25 price target on the ASX share. Based on its current share price of $4.14, this implies potential upside of 50% for investors over the next 12 months.
Morgans thinks that Catapult is well-placed to deliver strong top line growth through to at least 2028. It said:
Catapult Sports Ltd (CAT) is a global leader in sports performance technology that provides a comprehensive all-in-one platform for elite professional and collegiate sports. This encompasses coaching, scouting, analytics and athlete management. Initially landing with its core wearables technology, CAT has since expanded its service offering and opened up new key verticals assisting its penetration into a large addressable market of ~20k teams globally. We forecast strong topline growth for CAT, estimating a ~20% ACV 3-year CAGR, reaching ~US$180m by FY28. A scalable platform and strong SaaS metrics should see CAT join the 'Rule of 40' club by FY27. We initiate coverage on Catapult Sports (CAT) with a Buy recommendation and a A$6.25 per share price target.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX share with the potential to deliver big returns next year according to experts is radiopharmaceuticals company Telix.
Bell Potter has a buy rating and $23.00 price target on its shares. This is almost double its current share price.
The broker is expecting a better year for Telix, supported by the potential approval of its Zircaix product. It explains:
We are confident regarding the approval in CY 2026 of Zircaix following resubmission of the Biological License Application (BLA). The FDA rejected the original BLA due to CMC (chemistry manufacturing & control) matters at Telix's manufacturing partner. There were no matters related to safety or efficacy. We expect the market for Zircaix once approved will be in excess of US$500m. The product has been included in guidelines for disease management in the US and Europe and continues to be available in the US under the expanded access program. Elsewhere, sales of Iluuccix/ Gozellix in the PSMA franchise continue to grow and were recently boosted by the refresh on the pass through pricing.
